Nuvation Bio posted $45 million in total revenue for Q3 2026, driven by $27.5 million from IBTROZI sales, which remains the top prescribed ROS1 inhibitor for NSCLC. The FDA approved an updated label for IBTROZI reflecting a median response duration of 49.7 months and granted Fast Track status to safusidenib for IDH1-mutant glioma. The company holds $663.4 million in cash and plans to advance safusidenib through multiple Phase 2 and 3 trials. These developments position Nuvation Bio strongly in targeted cancer therapies with ongoing clinical progress and market leadership.
Nuvation Bio shares trade at USD 4.57 on Pluang as of Nov 05, 2026 04:11 WIB, down 2.56% in one day. The stock has a market cap of $1.65 billion and a 52-week low of $4.05. Despite recent price pressure, Pluang users show 100% buy interest with an average hold time of 13 days.
